Newman Dignan & Sheerar Inc. Reduces Holdings in Merck & Co., Inc. $MRK

Newman Dignan & Sheerar Inc. decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 34.2% during the fourth quarter, Holdings Channel.com reports. The fund owned 29,420 shares of the company’s stock after selling 15,275 shares during the period. Newman Dignan & Sheerar Inc.’s holdings in Merck & Co., Inc. were worth $3,097,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Cliftonlarsonallen Wealth Advisors LLC grew its stake in shares of Merck & Co., Inc. by 3.6% during the fourth quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 35,206 shares of the company’s stock worth $3,706,000 after acquiring an additional 1,237 shares during the last quarter. Sutton Place Investors LLC grew its stake in shares of Merck & Co., Inc. by 13.7% during the fourth quarter. Sutton Place Investors LLC now owns 6,054 shares of the company’s stock worth $637,000 after acquiring an additional 728 shares during the last quarter. Jackson Square Capital LLC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $1,021,000. Franklin Street Advisors Inc. NC grew its stake in shares of Merck & Co., Inc. by 462.8% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 142,541 shares of the company’s stock worth $15,004,000 after acquiring an additional 117,213 shares during the last quarter. Finally, Woodmont Investment Counsel LLC grew its holdings in shares of Merck & Co., Inc. by 1.9% during the fourth quarter. Woodmont Investment Counsel LLC now owns 170,507 shares of the company’s stock valued at $17,948,000 after buying an additional 3,189 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $123.25 on Thursday. The business’s 50 day moving average price is $118.54 and its 200 day moving average price is $104.06. The firm has a market cap of $304.73 billion, a P/E ratio of 16.93, a P/E/G ratio of 2.44 and a beta of 0.26. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $125.14. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same period in the prior year, the company earned $1.72 earnings per share. The firm’s revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, sell-side analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 37,685 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the sale, the executive vice president owned 160,174 shares in the company, valued at approximately $19,368,240.08. This represents a 19.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Jennifer Zachary sold 121,573 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $119.15, for a total value of $14,485,422.95. Following the completion of the sale, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 320,176 shares of company stock valued at $38,281,735 in the last 90 days. 0.13% of the stock is currently owned by insiders.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck launched a cash tender offer to buy Terns Pharmaceuticals, accelerating an acquisition that expands its oncology and hematology pipeline ahead of patent expiries for key products — a strategic move that can support future revenue. Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
• Positive Sentiment: JPMorgan and other analysts have raised price targets / reiterated Overweight views on MRK, signaling institutional confidence that Merck shares still have upside — a catalyst for buying interest. JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock
• Positive Sentiment: Merck’s recent quarterly results beat estimates, revenue grew year-over-year and the company set FY2026 EPS guidance — underpinning valuation and investor confidence in near-term fundamentals. Strong Results Lifted Merck & Co (MRK) in Q4
• Positive Sentiment: Merck is highlighted among consistent dividend stocks, which can attract income-focused and defensive investors amid market uncertainty. Is Merck & Co. (MRK) One of the Best Consistent Dividend Stocks to Buy Right Now?
• Neutral Sentiment: Merck lowered its offer price for Terns after reviewing trial data, a detail that changes deal economics and signals the firm is calibrating cost vs. risk — ambiguous for MRK shareholders (lower cash outlay vs. potential pipeline concerns). Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
• Neutral Sentiment: Coverage pieces are reassessing Merck’s valuation after strong price momentum; momentum supports higher multiples, but some analysts flag S&P 500 reweighting and valuation headwinds. Assessing Merck (MRK) Valuation After Strong Recent Share Price Momentum
• Neutral Sentiment: Analysis explains the Terns deal’s role in Merck’s pipeline and how it could affect S&P 500 valuation exposure — useful context but not an immediate share-mover. Merck’s (NYSE:MRK) Terns Deal And S&P 500 Valuation Impact Explained
• Negative Sentiment: Some intraday weakness was reported recently as the broader market improved — a reminder that short-term pullbacks can occur even with positive headlines. Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
• Negative Sentiment: Commentary questioning whether Merck is overbought warns of near-term valuation risk after a big run — a potential headwind for momentum traders. Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought?

Wall Street Analyst Weigh In

MRK has been the topic of a number of research analyst reports. BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $82.00 to $130.00 in a report on Thursday, December 18th. Wells Fargo & Company boosted their price objective on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Finally, Cantor Fitzgerald boosted their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $127.59.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.